Rezvilutamide plus chemo for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male aged 18 or older.
- You have prostate cancer that has spread to other parts of the body and is still growing even after treatment with abiraterone and hormone therapy.
- Your doctor has checked your health and says you are well enough to receive chemotherapy (ECOG score 0 or 1).
- You agree to take the study drug Rezvilutamide along with docetaxel chemotherapy.
- You do not have another cancer that needs treatment, a history of seizures, or severe liver, kidney, heart, or immune system problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests a new pill, Rezvilutamide, for men with prostate cancer that was removed by surgery but has features that make it more likely to come back. It's an alternative for those who don't want or can't have radiation therapy after surgery.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Hear when a new Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.